Remodulin, Tyvaso, Trepulmix (treprostinil) is a small molecule pharmaceutical. Treprostinil was first approved as Remodulin on 2002-05-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against prostacyclin receptor. In addition, it is known to target prostaglandin E2 receptor EP4 subtype, prostaglandin D2 receptor, prostaglandin E2 receptor EP1 subtype, prostaglandin E2 receptor EP2 subtype, and prostaglandin E2 receptor EP3 subtype. Remodulin's patents are valid until 2029-03-29 (FDA).